| EPB0211 | Under-representation of women in HIV clinical trials: how can this still be happening? | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0212 | Implementation of long-acting cabotegravir and rilpivirine in vulnerable populations with complex needs: primary 48-week results of JABS | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0213 | Effects of Atripla® and ethanol co-administration on rat caput epididymis tissues: a study on morphometry and androgen receptor immunoreactivity | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0214 | Evaluation of prevention of parent to child transmission services available for pregnant women living with HIV in Larkana District, Sindh, Pakistan | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0215 | Evaluation of clinical outcomes of pregnant women living with HIV receiving prevention of parent to child transmission services in Larkana District Pakistan | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0216 | Participant-reported outcomes with long-acting lenacapavir-based regimens among heavily treatment-experienced people living with HIV in the CAPELLA clinical trial | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0217 | The relationship between tenofovir urine and tenofovir diphosphate dried blood spot concentrations among transgender adults switching from tenofovir disoproxil fumarate/emtricitabine to tenofovir alafenamide/emtricitabine for HIV pre-exposure prophylaxis | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0218 | Switching to dolutegravir/lamivudine (DTG/3TC) is non-inferior to continuing tenofovir alafenamide (TAF)-based regimens at Week 196: TANGO subgroup analyses | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0219 | Islatravir (MK-8591) has no meaningful effect on the pharmacokinetics of atorvastatin and metformin following coadministration | E-poster | Antiretroviral therapies and clinical issues in adults |
| EPB0220 | Probability of single tablet regimens BIC/FTC/TAF, E/C/F/TAF, RPV/FTC/TAF, DTG/RPV or DTG/ABC/3TC discontinuation at 18 months in real life settings in the ANRS-CO3 - AquiVIH-NA cohort | E-poster | Antiretroviral therapies and clinical issues in adults |